Hoth Therapeutics, Inc. (HOTH): Price and Financial Metrics

Hoth Therapeutics, Inc. (HOTH)

Today's Latest Price: $1.69 USD

0.02 (1.20%)

Updated Nov 27 1:00pm

Add HOTH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

HOTH Stock Price Chart Interactive Chart >

Price chart for HOTH

HOTH Price/Volume Stats

Current price $1.69 52-week high $7.25
Prev. close $1.67 52-week low $1.60
Day low $1.67 Volume 171,765
Day high $1.72 Avg. volume 421,021
50-day MA $1.84 Dividend yield N/A
200-day MA $2.77 Market Cap 22.71M

Hoth Therapeutics, Inc. (HOTH) Company Bio

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.

HOTH Latest News Stream

Event/Time News Detail
Loading, please wait...

HOTH Latest Social Stream

Loading social stream, please wait...

View Full HOTH Social Stream

Latest HOTH News From Around the Web

Below are the latest news stories about Hoth Therapeutics Inc that investors may wish to consider to help them evaluate HOTH as an investment opportunity.

The Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) 10X Genomics Inc (NASDAQ: TXG ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Beigene Ltd (NASDAQ: BGNE ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Evogene Ltd (NASDAQ: EVGN ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) InVitae Corp (NYSE: NVTA ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Incorporated (NASDAQ: PRLD ) (listed Thursday) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc...

Benzinga | September 29, 2020

Hoth Therapeutics inks research pact for COVID-19 testing device

Hoth Therapeutics ([[HOTH]] -3.8%) has entered into a research agreement with the George Washington University, related to the development of an in vitro diagnostic device that allows immediate detection of SARS-CoV-2 via a mobile device.Nanohole array-based device utilizes plasmonic system designed for high sensitivity and specificity for detecting the SARS-CoV-2 virus.The company...

Seeking Alpha | September 21, 2020

Hoth Therapeutics Enters into Sponsored Research Agreement for On-the-Go COVID-19 Testing Device

NEW YORK , Sept. 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement ("SRA") with the George Washington University ("GW") relating to the development of an in vitro diagnostic device that has the potential for testing by patients anywhere to allow public health professionals to immediately detect SARS-CoV-2 via a mobile device as an aid in the diagnosis of the COVID-19 infection. The device, which is based upon intellectual property rights licensed by Hoth from GW, is a nanohole array ("NHA") based plasmonic system being designed for high sensitivity and specificity for detecting the SARS-CoV-2 virus. The device uses a thin sheet of gold coated with virus-specific proteins ...

Benzinga | September 21, 2020

Hoth Therapeutics Appoints Stefanie Johns, Ph.D., as Chief Scientific Officer

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announces the appointment of Stefanie Johns, Ph.D., to the position of Chief Scientific Officer, effective September 2020. In her role, Dr. Johns will further advance Hoth's…

PR Newswire | August 31, 2020

The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDA...

Benzinga | August 25, 2020

Read More 'HOTH' Stories Here

HOTH Price Returns

1-mo -2.31%
3-mo -35.50%
6-mo -41.52%
1-year -65.86%
3-year N/A
5-year N/A
YTD -72.70%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7828 seconds.